FDA Grants Expanded Early Access to Pancreatic Cancer Drug Daraxonrasib
The U.S. Food and Drug Administration (FDA) approved expanded early access for the experimental pancreatic cancer drug daraxonrasib on May 1, 2026. This decision brings new hope for late-stage pancreatic ductal adenocarcinoma (PDAC) patients and has sparked enthusiastic discussion in the medical community about the broad potential of targeted therapy in oncology.
Drug Background
Daraxonrasib is an experimental drug targeting the KRAS G12D mutation. KRAS gene mutations are extremely common in pancreatic cancer, with approximately 30-40% of PDAC patients carrying this mutation. For decades, KRAS was considered an “undruggable” target until recent breakthroughs in targeted therapy technology made substantive progress possible.
According to the New York Times, the drug has shown encouraging efficacy in early clinical trials — some late-stage pancreatic cancer patients experienced significant tumor shrinkage, with a few cases achieving complete remission. This result represents a milestone in pancreatic cancer treatment, as the disease has long been called the “king of cancers” with a five-year survival rate of less than 13%.
Expanded Access Program
The FDA’s approval is for an “Expanded Access” protocol, also known as “Compassionate Use.” This mechanism allows patients with serious or life-threatening diseases to access experimental drugs before they receive full regulatory approval.
According to the Washington Post, CBS News reported that former Senator Ben Sasse is one of the beneficiaries of this drug, sharing his treatment experience publicly. This high-profile political figure’s involvement has further elevated public awareness of the drug.
Professional medical journals including OncLive and Targeted Oncology have both covered this development in detail, noting that the approval of the expanded access protocol means the drug has received the FDA’s basic safety endorsement, paving the way for large-scale clinical trials and eventual market approval.
The Pancreatic Cancer Treatment Challenge
Pancreatic cancer is one of the deadliest cancers globally, characterized by difficulties in early diagnosis, poor response to traditional chemotherapy, and low surgical resection rates. According to the American Cancer Society, approximately 66,000 people in the United States are expected to be diagnosed with pancreatic cancer in 2026, with about 51,000 dying from the disease.
Mayo Clinic’s recently developed REDMOD AI system has demonstrated the ability to identify pancreatic cancer signatures from CT scans an average of 16 months before diagnosis (as reported in today’s AI & Tech section), while daraxonrasib’s progress represents an important breakthrough on the treatment side. The combination of AI-assisted diagnosis and targeted therapy may be reshaping the entire pancreatic cancer care ecosystem.
Looking Ahead
Analysts note that if daraxonrasib can confirm its efficacy in large-scale Phase III clinical trials, it would represent a major breakthrough in pancreatic cancer targeted therapy — the first in decades. Currently, multiple pharmaceutical companies are competing in this space, including other targeted drugs aimed at KRAS G12C mutations.
The expanded access approval means eligible patients can access treatment before the drug’s formal market approval, but it also requires doctors and patients to fully understand the drug’s experimental nature and potential risks.
Source: New York Times | USA Today | Washington Post